Recent evidence further suggests that EZH2 may regulate pyroptosis in GBM through STAT3 signaling, and treatment with DZNep plus the STAT3 inhibitor SH-4–54 led to increased pyroptosis markers and higher levels of IL-1β and IL-18, indicating that modulating pyroptosis could offer novel therapeutic opportunities [279]. This evidence concerns the gene STAT3 and glioblastoma.